Business Wire

SEOUL-SEMICONDUCTOR

16.5.2019 15:02:10 CEST | Business Wire | Press release

Share
Seoul Semiconductor SunLike Series Natural Spectrum LEDs Promote Human Visual Comfort, Daytime Alertness, Mood and Sleep Intensity According to on a Recent Scientific Study

Seoul Semiconductor Co., Ltd. (KOSDAQ:046890), a leading global innovator of LED products and technology, announced that its SunLike Series natural spectrum LEDs have been identified as a key light source for promoting human well-being, based on the results of a recent comprehensive sleep study conducted by scientists at the University of Basel.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190516005262/en/

Seoul Semiconductor developed SunLike Series natural spectrum LEDs in collaboration with Toshiba Materials’ TRI-R spectrum technology in 2017 as the first LED light source to closely match the spectrum of natural sunlight. The two companies have since promoted this natural sunlight spectrum technology through its favorable effects on human well-being and sleep as a key value in the evolution of lighting.

There has been an increase in research activity on the relationship between light and human bio-function, including a recent scientific study focusing on the effects of light spectrum on sleep quality, visual comfort, well-being and daytime alertness conducted by Prof. Christian Cajochen and his team at the University of Basel in Switzerland, entitled: “Effect of Daylight LED on Visual Comfort, Melatonin, Mood, Waking Performance, and Sleep,” published in the Journal of Lighting and Research Technology published on March 24, 2019.

It is well established that light is one of the strongest control factors for human circadian rhythms, such as the secretion of the sleep promoting hormone melatonin. Thus, optimal lighting condition during daytime are crucial to prevent circadian rhythm disturbances which can lead to sleep disorders and other life-style related diseases. Over the past ten years, there have been related scientific studies in the fields of sleep, chronobiology, physiology, as well as the impact of light quality in elderly care.

According to Prof. Cajochen’s research, LED light sources with the same measured correlated color temperature (CCT) and intensity, but different spectral output, can have different effects on human behavior and physiology. LED light sources with a spectrum close to natural sunlight produced better visual comfort, more alertness, and happier moods in the morning and evening among the test participants, compared to those exposed to conventional spectrum LEDs. The research tested subjects’ visual comfort, circadian physiology, daytime alertness, mood, cognitive performance, and sleep after being exposed to both conventional LED light, and natural spectrum LED light for 49 hours in a laboratory setting.

Quoting from the paper: “We have evidence that a daylight [natural spectrum] LED solution has beneficial effects on visual comfort, daytime alertness, mood, and sleep intensity in healthy volunteers. Delta EEG activity (0.75–4.5Hz) was significantly higher after daylight-LED than conventional-LED exposure during the post-light exposure night.” [NOTE: Delta EEG (electroencephalogram) measurements record delta waves, the brain waves associated with Stage 3 non-rapid eye movement (NREM) sleep, or “slow-wave sleep” (SWS), and aid in characterizing the depth of sleep.]

By providing the same spectrum as sunlight and in the visible light range, SunLike Series natural spectrum LEDs deliver benefits to human well-being, consistent with the mechanisms of vision that impact both image forming and non-image forming aspects of the eye, as well as the control of circadian rhythms. While the qualities of artificial light have been described primarily with color and intensity thus far, SunLike Series natural spectrum LEDs have introduced light spectrum as another important factor in determining overall light quality.

“This research conducted by the University of Basel suggests another important aspect to the evolving direction of artificial light over the past eighty years. In addition to the properties of energy efficiency and long life, we have added the factor of ‘human well-being’ to modern LED light sources,” said Nam Ki-bum, sales executive vice-president of Seoul Semiconductor. “As the world’s first mass-produced LED devices to achieve natural sunlight quality, SunLike Series LEDs are advancing lighting technology in this important area as we continue to respond to market needs from our customers’ lighting applications.”

Contact:

Seoul Semiconductor Inc. North America Andrew Smith Tel: +1 (901) 831-6614 Email: andrew.smith@seoulsemicon.com

Asia and Europe Jeong-hee Kim Tel: +82-70-4391-8311 Email: jeonghee.kim@seoulsemicon.com

Link:

ClickThru

Social Media:

https://www.facebook.com/seoulsemiconductorglobal

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye